Johnson & Johnson (NYSE:JNJ - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research note issued to investors on Friday.
Several other equities analysts have also commented on the company. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their target price for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Guggenheim upped their target price on Johnson & Johnson from $164.00 to $167.00 and gave the company a "neutral" rating in a report on Thursday. Royal Bank Of Canada upped their target price on Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a report on Thursday. Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Finally, Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Eleven investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $174.11.
View Our Latest Stock Report on Johnson & Johnson
Johnson & Johnson Stock Up 0.4%
NYSE JNJ traded up $0.67 on Friday, hitting $163.65. 9,764,459 shares of the stock traded hands, compared to its average volume of 8,138,165. The stock has a 50-day moving average of $154.29 and a 200 day moving average of $154.97. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a market capitalization of $393.75 billion, a P/E ratio of 17.50, a price-to-earnings-growth ratio of 2.18 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The firm had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same quarter in the prior year, the firm posted $2.82 earnings per share. Johnson & Johnson's revenue for the quarter was up 5.8% compared to the same quarter last year. As a group, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Johnson & Johnson
A number of institutional investors have recently added to or reduced their stakes in the company. EWA LLC lifted its position in Johnson & Johnson by 26.8% in the second quarter. EWA LLC now owns 2,860 shares of the company's stock worth $437,000 after purchasing an additional 604 shares during the period. Philip James Wealth Mangement LLC lifted its position in shares of Johnson & Johnson by 13.5% during the 2nd quarter. Philip James Wealth Mangement LLC now owns 87,853 shares of the company's stock valued at $13,420,000 after acquiring an additional 10,438 shares during the last quarter. Gold Investment Management Ltd. lifted its position in shares of Johnson & Johnson by 1.5% during the 2nd quarter. Gold Investment Management Ltd. now owns 18,790 shares of the company's stock valued at $2,914,000 after acquiring an additional 279 shares during the last quarter. Naples Global Advisors LLC lifted its position in shares of Johnson & Johnson by 3.5% during the 2nd quarter. Naples Global Advisors LLC now owns 48,414 shares of the company's stock valued at $7,395,000 after acquiring an additional 1,655 shares during the last quarter. Finally, Pure Financial Advisors LLC lifted its position in shares of Johnson & Johnson by 40.9% during the 2nd quarter. Pure Financial Advisors LLC now owns 28,037 shares of the company's stock valued at $4,283,000 after acquiring an additional 8,140 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.
Johnson & Johnson Company Profile
(
Get Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
